For example, in 2007, pimobendan was approved by the US Food and Drug Administration to treat MVD-affected dogs once they have reached CHF, but not before heart failure
Second, PWS patients have relatively lower visceral adipose tissue (VAT) and higher subcutaneous adipose tissue (SAT) compared to BMI-matched controls, though with some disputes [1]
Its FDA-approved for a range of conditions, including hypertension and heart failure
Practitioners should provide comprehensive post-treatment care guidelines, ensuring patients are well-informed and prepared to manage any mild discomfort
Report any changes in vision immediately, including blurriness, dark spots, pain, or loss of vision in one eye
Gastrointestinal side effects such as nausea, vomiting, and constipation are most common during dose escalation